Simplex Trading’s Starling Oncology STLN Stock Holding History

Simplex Trading’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,806	Closed	-$5.54K	–	10172
2025 Q4	$6.43K	Buy	+1,806	New	+$6.7K	﹤0.01%	7284

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Simplex Trading's STLN Position: Q1 2026 in Review

Simplex Trading sold out of Starling Oncology (STLN) in Q1 2026, closing a stake of 1,806 shares — an estimated $5.54K sold.

Simplex Trading first reported a position in STLN in Q4 2025 and held it in 1 quarter. The position peaked at $6.43K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Simplex Trading reported no remaining Starling Oncology position as of Q1 2026 after selling out during the quarter.
Simplex Trading sold 1,806 Starling Oncology shares in Q1 2026, an estimated $5.54K.
Simplex Trading first reported a position in Starling Oncology in Q4 2025 and held it in 1 quarter.
Simplex Trading's Starling Oncology position peaked at $6.43K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.